A weekly dose escalation of regorafenib was superior to starting with the standard dose of 160 mg/day for patients with refractory metastatic colorectal cancer (mCRC), according to the ReDOS* trial presented at the ASCO GI Cancers Symposium 2018.
The androgen receptor inhibitor apalutamide prolonged metastasis-free survival (MFS) by approximately 2 years in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of metastatic disease, according to findings of the SPARTAN* trial.
Oncologists refer patients for genomic profiling to guide diagnosis, treatment options after standard therapy, or to determine eligibility for basket studies in cases of refractory and rare tumours. Next generation sequencing (NGS) is becoming to be the gateway to precision medicine in oncology. Elvira Manzano from MIMS Oncology spoke with Dr Federico Rojo from the Fundacion Jimenez Diaz University Hospital in Madrid, Spain on the impact of NGS on precision cancer therapy during a genomic oncology symposium in Singapore.
Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.
Combining axitinib with pembrolizumab results in an “unprecedented” objective response rate (ORR) in treatment-naïve patients with advanced renal cell carcinoma (RCC), results of an ongoing phase Ib trial have shown.
Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.
Combining the monoclonal antibody targeting PD-L1 atezolizumab and the antiangiogenic biologic bevacizumab with a chemotherapy of carboplatin + paclitaxel (CP) for treating non-squamous metastatic non-small-cell lung cancer (NSCLC) leads to significant improvement in progression-free survival (PFS) compared with bevacizumab + CP as first-line treatment, according to the IMpower150* trial presented at the ESMO Immuno Oncology Congress 2017.
University of Malaya (UM) is appointed as the Capacity Enhancement Hub in Health-Related Fields in Malaysia for Africa, Southeast Asia and developing countries by Merck Foundation, a philanthropic organization established in 2017. The appointment was sealed by the signing of a Memorandum of Understanding between various stakeholders.
Combining gabapentin or pregabalin with opioid analgesics does not significantly improve cancer pain relief compared with opioid monotherapy, according to results of a recent systematic review and meta-analysis.
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.